Bookmark
Forward
QuickView for Ergoloid mesylate (compound)
PubChem
| Name: | Ergoloid Mesylates |
|---|---|
| PubChem Compound ID: | 168870 |
| Description: | A mixture of the mesylates (methane sulfonates) of DIHYDROERGOCORNINE; DIHYDROERGOCRISTINE; and the alpha- and beta-isomers of DIHYDROERGOCRYPTINE. The substance produces a generalized peripheral vasodilation and a fall in arterial pressure and has been used to treat symptoms of mild to moderate impairment of mental function in the elderly. |
| Molecular formula: | C32H45N5O8S |
| Molecular weight: | 659.795 g/mol |
| Synonyms: |
14271-04-6; 9,10-Dihydroergocornine methanesulfonate; 9,10alpha-Dihydro-12'-hydroxy-2',5'alpha-diisopropylergotaman-3',6',18-trione methanesulphonate; C14053; EINECS 249-539-5; 29261-94-7
|
DrugBank
Identification
| Name: | Ergoloid Mesylates |
|---|---|
| Name (isomeric): | DB01049 |
| Drug Type: | small molecule |
| Description: | A mixture of the mesylates (methane sulfonates) of DIHYDROERGOCORNINE; DIHYDROERGOCRISTINE; and the alpha- and beta-isomers of DIHYDROERGOCRYPTINE. The substance produces a generalized peripheral vasodilation and a fall in arterial pressure and has been used to treat symptoms of mild to moderate impairment of mental function in the elderly. |
| Brand: | Hydrogenated Ergot Alkaloids, Dihydroergotoxine Mesilate, Ergoloid Mesylates [Usan], Hydergine LC, Alkergot, Dihydroergotoxin Mesilat, Ischelium, Hydergine, Dihydroergotoxine Mesylate, Hydergin, Circanol, Co-Dergocrine Mesylate, Dihydroergotoxine Methanesulfonate, Gerimal, Deapril-ST, Dihydroergotoxin Methanesulfonate, Dihydroergotoxine Methanesulphonate, Trigot, Dihydroergotoxin Mesylate, Redergin |
| Category: | Nootropic Agents, Vasodilator Agents, Sympatholytics, Adrenergic alpha-Antagonists |
| CAS number: | 8067-24-1 |
Pharmacology
| Indication: | For use as an adjunct therapy for patients with dementia |
|---|---|
| Pharmacology: |
Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some...
show more » |
| Mechanism of Action: | Ergoloid mesylates act centrally, decreasing vascular tone and slowing the heart rate, and acts peripherally to block alpha-receptors. One other possible mechanism is the effect of ergoloid mesylates on neuronal cell metabolism, resulting in improved oxygen uptake and cerebral metabolism, thereby normalizing depressed neurotransmitter levels. |
| Absorption: | Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism. |
| Protein binding: | 98-99% |
| Biotransformation: | Hepatic. |
| Half Life: | 3.5 hours |
| Toxicity: | Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
Enzymes
